|
WO2021057451A1
|
|
Antibody fusion protein, preparation method therefor and use thereof against anti-tumor
|
|
WO2020103629A1
|
|
Anti-her2/pd1 bispecific antibody
|
|
WO2020103630A1
|
|
Anti-egfr/pd-1 dual specific antibody
|
|
CN111620949A
|
|
Antibodies that bind human LAG-3, methods of making, and uses thereof
|
|
CN110872349A
|
|
Antibodies that bind human IL-4R, methods of making, and uses thereof
|
|
CN110818789A
|
|
Purification method of high-purity cynomolgus monkey interleukin 17A
|
|
CN110790840A
|
|
Antibodies that bind to human HER2, methods of making and uses thereof
|
|
CN109942706A
|
|
Monoclonal antibody, preparation method and use in conjunction with people IL-5
|
|
CN109929793A
|
|
A kind of culture medium for high expression monoclonal antibody
|
|
CN109748955A
|
|
A kind of affinity chromatography medium and application suitable for antibody purification
|
|
CN109745559A
|
|
The liquid preparation of the monoclonal antibody of anti-human IL-17A
|
|
CN109748963A
|
|
A kind of monoclonal antibody of anti-lag-3 and its preparation method and application
|
|
CN109745558A
|
|
A kind of stable Anti-X activity preparation
|
|
CN109311974A
|
|
Anti-human Interleukin-17 A monoclonal antibody, preparation method and application
|
|
CN108341871A
|
|
Anti- PD-1 monoclonal antibodies and its preparation method and application
|
|
CN108018302A
|
|
A kind of screening technique of high expression foreign protein stable cell line
|
|
CN107870232A
|
|
A kind of biological activity detection method for RANKL target therapeutic agents
|
